Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Our clinical-stage product candidates include:
- Phase 3 HEPLISAV ™ Hepatitis B Vaccine
- Phase 1 Universal Flu Vaccine
- Phase 1 Hepatitis C Therapy
- Phase 1 Hepatitis B Therapy
In addition, we have an oligonucleotide-based Toll-like Receptor (TLR) inhibitors, called immunoregulatory sequences (IRS), being readied for clinical studies by the end of 2010. We also have programs partnered with pharmaceutical companies, including AstraZeneca and GlaxoSmithKline.
Our European subsidiary Rhein Biotech manufactures hepatitis B surface antigen for HEPLISAV. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.
For more information visit www.dynavax.com.